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! 


" To describe and compare adherence and persistence with inhaled therapies in 
patients with asthma or COPD in the United Kingdom (UK). 
" A retrospective prescribing database cohort was obtained from 44 
general practitioner surgeries in NHS Forth Valley Scotland. Patients with physicianC
diagnosed asthma or COPD who received inhaled therapy between January 2008 
and December 2009 were included. Four classes of inhaled therapy were assessed: 
inhaled corticosteroids; longCacting betaCagonists; combination therapy inhalers and; 
longCacting muscarinic antagonists. Adherence was calculated using the medication 
possession ratio (MPR) and persistence was determined using KaplanCMeier 
survival analysis for the time to discontinuation (TTD) over one year. Two stepCwise 
logistic regressions were performed to assess the contribution of diagnosis to 
adherence/persistence. 
12,923 patients were included in the analysis: 10,177 patients with 
asthma and 2,746 patients with COPD. 24.8% of medication episodes for asthma 
and 45.0% of medication episodes for COPD were classified as having an adequate 
medication supply (MPR of 80C120%). The overall median TTD was 90 days (IQR: 
50C184 days) for patients with asthma and 115 days (58C258 days, comparison 
p<0.001) for patients with COPD. Patients with COPD were found to be more likely 
to achieve an MPR of at least 80% (OR: 1.32, 95% CI: 1.20C1.46), but had a similar 
likelihood of persistence at one year to patients with asthma. 
#
#Adherence and persistence with respiratory therapies in the UK is 
relatively low. There is suggestion that patients with COPD may display more 
adherent behaviours than patients with asthma. 
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
$%&'!
 Patients with respiratory disease are particularly likely to have poor adherence 
to medicines due to complex medication regimens and difficulty using inhaler 
devices. 
 It is unknown whether patients with asthma and COPD have different 
medication use behaviours. 
 
$!
 Adherence for maintenance inhaler therapies in respiratory disease is low, but 
higher among patients with COPD compared to patients with asthma. 
 Less than 20% of patients in this UK cohort with respiratory disease remained 
persistent with inhaled therapy at one year. 
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"( 


# 
#

Medication adherence refers to the degree to which a patient’s medicationCtaking 
behaviour coincides with agreed medical advice, and largely has supplanted the 
term ‘compliance,’ which infers a clinicianCdirected therapy decision without patient 
input.[1] Medication persistence examines whether a patient follows the 
recommendation of continuing treatment for a prescribed length of time.[2] According 
to the World Health Organization (WHO), approximately half of patients across the 
world are nonCadherent with treatment prescribed for chronic disease, leading to 
decreased treatment effectiveness, decreased patient quality of life, and increased 
healthcare costs.[1] As clinical research develops new therapies for patients with 
chronic disease it is important to identify and optimise medication taking 
behaviours.[3C4] 

Treatment nonCadherence in respiratory disease is particularly common. For patients 
with asthma, reported nonCadherence rates range from 30C70%[5] and are thought to 
contribute significantly to the prevalence of severe refractory disease.[6] Most 
studies quantifying adherence in asthma have focused on children although adults 
are of equal concern as nonCadherence occurs across all demographic categories.[7] 
In patients with chronic obstructive pulmonary disease (COPD), complex medication 
regimens and multiple comorbidities result in adherence rates of approximately 
50%.[8] A lack of perceived benefit led to 30% of patients with COPD intentionally 
discontinuing their therapy in one analysis.[9] For both conditions, rates of nonC
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adherence reported in clinical trials are likely to be underestimated due to the type of 
patients selected for trials and the influence of the trial environment itself. 
 
Respiratory disease presents a unique challenge for patient adherence/persistence. 
In addition to the common barriers that all patients with chronic disease face, a 
number of deviceCrelated factors complicate the situation, including dislike of inhaled 
formulations, improper inhaler technique, and need for additional equipment such as 
spacers.[10] Of additional importance is how patients perceive their disease in terms 
of severity and awareness,[11] which for respiratory disease – with a variable 
symptom time course in asthma, and misunderstanding of disease symptoms as 
‘normal’ in COPD – is an important contributor. 
 
Almost all available respiratory medications are utilised in the treatment of both 
asthma and COPD. Accordingly, some studies have analysed adherence jointly 
without regard to diagnosis,[12C13] despite the different pathology, symptoms and 
management of each condition. To our knowledge, no single analysis has compared 
the differences in respiratory medication utilisation between patients with asthma or 
COPD, and accordingly, the aim of this study was to describe and compare 
adherence and persistence with inhaled therapies for patients with physicianC
diagnosed asthma and COPD in the United Kingdom (UK). 
 
" 

The present study is a retrospective database cohort analysis of prescribing data 
from National Health Services (NHS) Forth Valley in Scotland. Data were provided 
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by the NHS Forth Valley Airways Managed Clinical Network in coordination with the 
ECPRS clinical recording tool program (Campbell Software Solutions©, Irvine, UK). EC
PRS was designed as a computerCintegrated clinical audit program to improve 
clinical care at practice level (described elsewhere[14]) but in short, collectively 
formed a database of patients with physicianCdiagnosed asthma and/or COPD 
treated in 44 general practitioner (GP) surgeries from 2007 to 2009. The reference 
health board covers a geographic population of nearly 300,000 patients, while the 
database contains information on approximately 22,000 distinct patients with 
physicianCdiagnosed asthma/COPD. The departmental ethics group at the University 
of Strathclyde determined no formal ethics review was needed for use of the dataset. 
 
Patients (children and adults) included in the analysis had (1) a GPCrecorded 
diagnosis of asthma or COPD, and (2) at least one prescription issued for a 
qualifying inhaled maintenance medication between January 1, 2008, and December 
31, 2009 (the study period), including inhaled corticosteroids (ICS), longCacting beta 
agonists (LABA), ICS/LABA combination therapy inhalers, or longCacting muscarinic 
antagonists (LAMA). Patients were assessed separately by diagnosis, and patients 
with a recorded dualCdiagnosis of asthma and COPD were excluded from the 
analysis. Demographic characteristics for each group were assessed, including age, 
sex, maintenance medications received, and the proportion of patients who were 
prescribed reliever medications (shortCacting beta agonists [SABA] and oral 
corticosteroids [OCS]) during the study period.  
 
	

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Medication adherence was assessed by calculating the medication possession ratio 
(MPR) for each class of maintenance therapy received. Similar to other 
analyses,[12,15C16] MPR was calculated by summing the days of medication supply 
provided and dividing by the total time treated: 
 
100% x 
fills last and first between days
supply medication of days total
  MPR   
 
Medication supply was calculated according to the posology and inhaler size (e.g. 
60Cdose inhaler with prescriptive instructions of 1 inhalation twice daily = 30 days 
supply) for each prescription. A sequence of at least two prescriptions during the 
twoCyear study period was required to calculate an MPR. The calculation was 
specific to therapeutic class, but not to dose or individual pharmacological agent. 
Thus, a patient receiving sequential treatment with two different ICS inhalers (e.g. 
fluticasone switched to beclometasone) or having a change in the dose midCtherapy 
would have a single MPR calculation. However, a single patient may have multiple 
MPRs if they received medications from more than one therapeutic class, such as 
treatment with an ICS changed to treatment with a combination therapy inhaler. After 
individual MPRs were calculated for each patient and medication, they were 
aggregated by therapeutic class: ICS, combination therapy inhalers, LABA (for 
patients with asthma or COPD), and LAMA (only for patients with COPD). The use of 
LAMA was not quantified for patients with asthma due to a lack of treatment 
recommendation in prevailing clinical guidelines. The proportion of patients having 
achieved an adequate medication supply, defined as an MPR between 80 and 
120%,[17] was also determined; MPRs less than 80% or over 120% were defined as 
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undersupply or oversupply, respectively. The amount of SABA (in doses/day) 
prescribed during each MPR was also quantified. This was achieved by summing the 
number and size of SABA inhalers to determine the number of total SABA doses 
prescribed, and then dividing by the number of days over which the maintenance 
inhaler was prescribed (the denominator of the MPR calculation). 
 

Medication persistence was evaluated using a refillCsequence model and defined as 
the difference in time between the first prescribing of a medication during the study 
period and either the last prescribing, or an nonCpermissible gap in therapy 
(whichever occurred first).[18C19] A patient was considered to have an unacceptable 
gap if they failed to receive a prescription within 30 days after their previous 
medication supply was due to run out. Patients were also classified by whether they 
were on new or established therapy during the study period; patients were 
considered to be on ‘new’ therapy if they had no history of being prescribed an agent 
in the specified therapeutic class in the six months prior to the start of the study 
period. At least one prescription for a maintenance medication during the first year of 
the twoCyear study period was required to enable accurate calculation of a oneCyear 
persistence rate. Median time to discontinuation (TTD) for each patient by 
therapeutic class was calculated using a KaplanCMeier survival anal sis, with a time 
censor utilised at one year postCmedication initiation.  
 

Two binary logistic regression models were utilised to separately assess predictors 
of adherence and persistence. For adherence, the outcome of interest was 
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achievement of an MPR of at least 80% (including both adequate supply and 
oversupply); this binary measure was chosen over a continuous measure since 
oversupply does not confer any demonstrable therapeutic benefit over adequate 
supply. For persistence, a  consideration of the KaplanCMeier results 
suggested a nonCproportionality of hazards over time; therefore, logistic regression 
(with an outcome of interest of persistence past 100 days of therapy) was utilised 
over a Cox regression analysis. PatientC and treatmentCrelated variables of interest 
(age, sex, diagnosis, therapeutic class of medication) were assessed first in 
univariate fashion; SABA and OCS utilisation (doses/day and receipt [yes/no], 
respectively) during the study period were also entered in adherence model to 
include a measure of disease control, and classification of treatment as 
new/established therapy was utilised in the persistence model. Significant variables 
from the univariate analysis were filtered into the final forward stepwise multivariate 
models, with α set at 0.05 for entry and 0.10 for removal. Results were reported with 
odds ratios (OR) and 95% confidence intervals (CI). 
 
Minitab® 16 statistical software (Minitab Ltd., Coventry, UK) was used for analysis. A 
MannCWhitney test was used to compare differences between continuous measures 
(median age, median doses/day of SABA), while chiCsquared tests were used to 
assess categorical differences (demographics, classification of medication supply). A 
Wilcoxon test was used to test for differences in persistence as assessed by the 
KaplanCMeier analysis. A Bonferroni correction was applied to minimise error 
resulting from multiple comparisons when appropriate. 


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
)!!!
A total of 12,923 patients were included in the analysis, 10,177 patients with asthma 
and 2,746 patients with COPD (*). Patients with asthma were more likely to 
be female, and the median age of patients was predictably younger and more 
variable than those with COPD. More patients with asthma (8873; 87.2%) than with 
COPD (2746; 65.4%) were treated with a single therapeutic class of medication 
during the study period (p<0.001). Patients with either disease were prescribed 
SABA in similar proportions, although the use of OCS was greater among those with 
COPD. A total of 17,354 episodes of maintenance medication use were assessed: 
11,618 for asthma patients and 5,736 for COPD patients. 
 
"!!
 
Overall 24.8% (95% confidence interval [CI]: 24.0C25.6%) of medication episodes for 
asthma and 45.0% (95% CI: 43.7C46.3%) of medication episodes for COPD were 
classified as an adequate supply (p<0.001 for comparison). The proportion of 
patients with an adequate MPR also varied according to therapeutic class (+). 
Adequate supply was highest for LAMA inhalers in patients with COPD at 52.2%; 
patients with COPD had higher incidence of adequate supply and lower incidence of 
undersupply for all three therapeutic classes available for comparison. Undersupply 
accounted for approximately oneCthird to oneChalf of all episodes, with all therapies 
for patients with asthma having an undersupply rate of greater than 50%. Oversupply 
of medication was particularly common for prescribing of ICS in both diseases, at 
27.0% for asthma and 34.8% for COPD. 
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In the logistic regression for adherence, both male sex and increasing age were 
associated with higher odds of achieving an MPR of at least 80% (,). Both a 
diagnosis of COPD and treatment with LAMA were associated with higher odds, 
although these effects were softened in the multivariate analysis with inclusion of 
other variables. The number of doses/day of SABA prescribed during the study 
period increased alongside MPR, with each additional dose/day correlating to an 
11% increase in the odds of achieving an adequate MPR; receiving a prescription for 
OCS was also associated with an increased odds of an adequate MPR, although this 
effect failed to meet significance for inclusion in the multivariate model. 
 
"!!

For asthma, the overall median TTD was 90 days (IQR: 50C184 days) and for COPD, 
the overall median TTD was 115 days (IQR: 58C258, comparison p<0.001); the 
percentage of patients persisting at one year was 11% and 16% for asthma and 
COPD, respectively (-	*). Persistence by therapeutic class was greater for 
patients with COPD than asthma for both LABA (96 vs. 61 days, p=0.008) and 
combination inhalers (116 vs. 85 days, p<0.001), but similar for ICS (101 vs. 100 
days). The highest persistence overall was seen for LAMA inhalers in COPD, with a 
median TTD of 123 days and 18% of patients persisting after one year.  
 
In the logistic regression for persistence, male sex and age were associated with 
higher odds of persisting past 100 days of therapy (.). Therapy with a LAMA 
or ICS produced the similarly highest odds among therapeutic classes, but diagnosis 
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failed to meet significance for inclusion in the final model. Newly initiated therapy 
was associated with 19% lower odds of persisting past 100 days, compared to 
patients on already established therapy. 

 

#
 
The current analysis demonstrates a relatively low rate of adherence/persistence for 
inhaled therapies for the treatment of respiratory disease, and reveals that among 
use of the same medications, patients with asthma and COPD display different 
medication use behaviour. 
 
Less than oneCquarter of patients with asthma and less than oneChalf of patients with 
COPD were classified as having an adequate medication supply. Other studies using 
administrative dispensing databases have demonstrated similar rates to those found 
in this prescribing analysis.[12C13,15C16,20C21] However, to the best of our 
knowledge, no single analysis has demonstrated enhanced adherence among 
patients with COPD for the same inhaled therapies within an adjusted analysis. 
There is evidence that patients with COPD display more adherent behaviours as 
they age,[22] and similarly our analysis found that age over 40 years is an 
independent contributor to having an adequate medication supply. However, older 
patients also face unique barriers that complicate medication adherence and may 
not be captured with prescribing data, including cognitive decline, lack of dexterity 
and polypharmacy.[23] Patients with COPD may also experience more consistent 
and severe disease symptomology, and may be inclined to be more adherent than 
patients with asthma. Although the inclusion of patients prescribed more than 
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reliever therapy would presume that the population studied had a chronic form of 
asthma, the natural episodic time course of patient symptoms in asthma may have 
resulted in sporadic treatment periods interlaced with drugCfree intervals, rendering a 
lower level of overall adherence. 
 
Adherence to prescribed therapy has been shown to have an association with 
disease outcomes in respiratory disease, resulting in lower rates of emergency room 
visits and hospitalisations.[24C26] Other measures of disease control, such as 
exacerbation rates, may be less sensitive and require high levels of adherence to 
provide noticeable improvement.[27] Our multivariate analysis found that patients 
with higher level prescribing of SABA reliever therapy were more likely to have 
higher level prescribing of their maintenance therapy, a relationship that has been 
detected previously.[15,28] It may be expected that a high use of reliever therapy 
should correspond with poor adherence to maintenance therapy; accordingly, it has 
been suggested previously that symptomatic patients may have a weaker sense of 
control and ownership of their illness, resulting in lo er motivation and overall 
medication adherence.[29] However, the direction of causation in the relationship 
between reliever and maintenance therapy is unclear, as patients who are 
symptomatic as defined by increased use of reliever therapy may be inclined to 
develop better adherence to their maintenance therapy.[1] The perceived necessity 
of a medication by the patient has also been shown to correlate with adherence[29] 
and the relative severity of the disease consequences[11,30] may further complicate 
the situation. 
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More than 80% of patients failed to remain on prescribed therapy at 12 months postC
initiation, not unlike an analysis of Canadian claims data that found a range of 47 – 
93% for nonCpersistence at one year among inhaled therapies.[31] Medication 
persistence calculations are sensitive to how stringent the definition is for an 
allowable medication gap. The current analysis set this threshold at 30 days; a 
 sensitivity analysis extending this gap to 60 days increased the overall median 
TTD to 114 days (20% persisting at one year) for asthma and 152 days (22% 
persisting at one year) for COPD, respectively (data not shown). Despite these 
results, the enhanced effect of COPD diagnosis seen in the regression for 
adherence failed to replicate in the regression for persistence. Medication 
persistence is not only a measure of longCterm adherence, but also of treatment 
stability, as the TTD may be influenced by patients with therapy changes, such as for 
patients with asthma ‘stepping up’ from ICS therapy alone to ICS/LABA combination 
inhaler therapy. The percentage of patients treated with more than one class of 
maintenance therapy was significantly higher among patients with COPD than with 
asthma and likely softened the effect of both COPD diagnosis and treatment with 
LAMA in the multivariate regression for persistence – both variables that were 
significant on a univariate basis, and significant within the adherence regression. The 
shape of persistence curves and the further lessened persistence among patients 
with newly initiated therapy suggests that the overall low persistence is primarily 
influenced by the large dropCoff of patients early in therapy, often after the first 
couple of prescriptions. Accordingly, initiation of therapy appears to be an 
appropriate target for promoting good medicine use in patients with respiratory 
disease. Although no single set of interventions has been successful in consistently 
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improving adherence, [3] our results would suggest that research should focus 
efforts during the first three months of therapy. 
 
Among the inhaled therapies assessed, LAMAs were associated with the best 
adherence/persistence, which may be a function of the increased convenience of 
onceCdaily dosing.[32] Medication adherence is known to decrease as dosing 
frequency increases,[33] and all other therapies in the present analysis have a 
standard twiceCdaily dosing regimen. Therapy with an ICS had the lowest percentage 
of patients (with either disease) identified as having an adequate level of medication 
supply (MPR 80C120%), but was also found to have a comparatively high rate of 
adherence/persistence in the regression analyses. For adherence, this was likely 
influenced by the inclusion of oversupply in the binary outcome, but for persistence, 
the reasons are less clear. There may have been some influence of inhaler size on 
the results, as most available combination therapy inhalers and LABAs are packaged 
in 60Cdose or 120Cdose units, largely corresponding to a 30Cday supply per inhaler. 
However, the most commonly utilised ICSs in this analysis are supplied in 200Cdose 
units, which may correspond to as much as a 100Cday supply for a single inhaler. 
This may have led to higher odds of persistence for ICS within our calculations, as a 
single prescribing event provides a longer medication supply. An additional point to 
consider is the effect that ICS dose titration may have on adherence and 
persistence. It is possible that clinicians may initially prescribe a higher dose of ICS 
(or a higher number of puffs from an inhaler) which is then scaled back based on the 
patient’s symptoms; this may explain some variation in the results. 
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There are several limitations with the current study. All database studies estimate 
adherence/persistence as it is not always feasible to obtain serum drug 
concentrations or individually assess patients in large numbers. Access to 
medication is used as a proxy for adherence in this study and thus we are unable to 
discern whether the patient actually takes the medication or if he/she uses an inhaler 
device correctly; therefore, by definition the results are ceiling estimates. 
Furthermore, the current study used prescribing data obtained from the GP. 
Prescriptions are generally written for an initial supply, and a patient only continues 
therapy by obtaining a new prescription, either by visiting the GP themselves, or 
more commonly through a ‘managed repeat’ service where the pharmacist 
communicates with the GP for further supply. While the first prescription is initiated 
by the GP, there is a great degree of patientCinitiated action required for followCup 
supply, which may influence the largeCdrop off seen early in therapy. Similarly, 
hospitalisations, particularly for patients with COPD may lead to changes or 
disruptions in therapy that effect the calculations. Lastly, the regression models 
provide an indication of the variables when considered together, but indicate (via the 
cCstatistic) that other variables that were unable to be accounted for within this 
analysis likely have an effect on the outcome; however, this modest fit is a common 
finding among adherence studies.[34] In particular, in a prescribing database, we 
were unable to correlate the results of the regression with clinical outcomes, such as 
hospitalisations and overall disease control. However, we attempted to include a 
proxy for symptoms by quantifying SABA and OCS utilisation among patients. 
 
In conclusion, adherence and persistence with respiratory therapies in this UK cohort 
was relatively low. There is indication that patients with COPD may display more 
Page 18 of 29
International Journal of Clinical Practice
International Journal of Clinical Practice
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
19 
 
adherent behaviours than their counterparts with asthma. Efforts to increase 
medication persistence should likely be targeted to focus followCup efforts during the 
first months of therapy. 

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(n=2746) 
Male sex 4317 (42.4) 1367 (49.8) ‡ 
Median age, years (IQR) 41 (22 – 57) 70 (63 – 77) ‡ 
< 20 years 2204 (21.7) 0 (0) 
20(39 years 2561 (25.2) 7 (0.3) 
40(59 years 3235 (31.8) 418 (15.2) 
60(80 years 1900 (18.7) 1853 (67.5) 
≥ 80 years 277 (2.7) 468 (17.0) 
Therapies received   
ICS 6520 (64.1) 682 (24.8) ‡ 
CMB 4087 (40.2) 1504 (54.8) ‡ 
LABA 874 (8.6) 274 (10.0) † 
LAMA N/A 1736 (63.2) 
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CI: confidence interval; CMB: combination therapy inhaler; COPD: chronic obstructive pulmonary 
disease; ICS: inhaled corticosteroid; LABA: long"acting beta"agonist; LAMA: long"acting muscarinic 
antagonist; N/A: not applicable; OCS: oral corticosteroids; OR: odds ratio; SABA: short"acting beta 
agonist 
7univariate analysis with MPR ≥ 80% utilised as outcome 
8multivariate analysis adjusted by sex, age, diagnosis, therapeutic class and SABA utilisation, with 
MPR ≥ 80% utilised as outcome 
9model fit assessed by c"statistic: 0.68 (95% CI: 0.67"0.69) 
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CI: confidence interval; CMB: combination therapy inhaler; COPD: chronic obstructive pulmonary 
disease; ICS: inhaled corticosteroid; LABA: long"acting beta"agonist; LAMA: long"acting muscarinic 
antagonist; N/A: not applicable; OR: odds ratio 
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